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Abstract
OBJECTIVE: The objective of this selective EBM review is to determine whether or not the use
of probiotics treat abdominal pain in children between the ages of 4 and 18 with irritable bowel
syndrome.
STUDY DESIGN: Systemic review of three randomized controlled trials (RCTs) published after
2007, all English language.
DATA SOURCES: All three randomized controlled trials were found on PubMed and were
selected based on relevance to the proposed clinical question.
OUTCOMES MEASURED: Main outcomes measured were duration with and without
abdominal pain, severity of pain, postprandial swelling, belching-abdominal distention, difficulty
in defecation, urgent defecation, and feeling of incomplete defecation. Outcomes were measured
by using Wonger-Baker FACES pain rating scale, five-point likert scale, and a self-reported
questionnaire.
RESULTS: Two studies found no significant improvement in abdominal pain or discomfort
when comparing probiotics to placebo when treating irritable bowel syndrome. One study found
a significant improvement in abdominal pain when comparing probiotics to placebo. When
looking at efficacy of probiotics, two studies had a relatively low number needed to treat.
CONCLUSION: From the three randomized controlled trials, it can be concluded that treating
children with irritable bowel syndrome between the age of 4 and 16 with probiotics is
inconclusive. Further research is warranted.
KEY WORDS: Irritable bowel syndrome and probiotics
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INTRODUCTION:
Irritable bowel syndrome, according to Rome III criteria, is defined as abdominal pain or
discomfort associated with relief after defecation, change in stool frequency and/or a change in
stool consistence.1 According to the National Institute of Diabetes and Digestive and Kidney
Disease, IBS is diagnosed when a child, who is growing as expected, has abdominal pain or
discomfort once per week for at least 2 months without other disease or injury that could explain
the pain.2 IBS has varying symptoms including cramping, bloating, diarrhea, constipation, or
alternating diarrhea and constipation. IBS is not life-threating but can impact daily activities and
quality of life.3
Irritable bowel syndrome is the most common gastrointestinal diagnosis among
gastroenterology practices in the United States.2 It is also one of the top 10 reasons patients visit
their primary care physician.2 According to reported studies, the disease prevalence is lower in
the Hispanic, Asian and black population.3 In a pediatric population, males and females are
equally affected.3 IBS symptoms are reported in 14% of high-school students and 6% of middleschool students.3 Irritable bowel syndrome is not described in preschool-aged or in younger
children because the diagnosis depends on the child’s ability to report detailed symptoms.3
Children who have a history of recurrent abdominal pain are at increased risk of developing IBS
in the future.2
Due to high prevalence of this condition, there is a definite economic burden in the
United States. The exact number of pediatric visits per year is unknown but in the general
population there are between 2.4 and 3.5 million annual visits.3,4 Not all individuals with IBS
symptoms obtain medical care.4 Most physicians diagnose IBS using diagnosis of exclusion
because there are no diagnostic studies available. Using this method to diagnose IBS leads to
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extensive and unnecessary testing.5 The direct cost for the general population has been estimated
to range from $1.5 to $10 billion per year.5 These figures do not take into account prescriptions
and over-the counter medications which can further increase the expenditure. The indirect cost of
IBS has been estimated to be much greater, approaching $20 billion per year.5
The cause of IBS is unknown. Researchers believe a combination of physical and
abnormal psychotic disorders can lead to irritable bowel syndrome.2 Possible causes of IBS in
children include signal disruption between the brain and GI tract, abnormal GI motility,
hypersensitivity to abdominal pain, anxiety, depression, bacterial gastroenteritis, small intestinal
bacterial overgrowth, and genetics.2
Irritable bowel syndrome is not a disease; it is a group of symptoms that occur together.2
Unfortunately there is no cure for IBS. Treatment is based on symptoms patients are
experiencing. Symptoms can be treated with dietary changes, medication, probiotics, and
therapy.2 Medications commonly used include fiber supplements, laxatives, antidiarrheals,
antispasmodics, and antidepressants. Cognitive behavioral therapy, psychodynamic/interpersonal
therapy, and hypnotherapy can help reduce stress and improve IBS symptoms.2
Probiotics have multiple beneficial effects in the gastrointestinal tract, such as increasing
the mass of bacterial microflora, decreasing bacterial overgrowth, inducing the intestinal
mucosal barrier, and normalizing the motility of the digestive tract.6 Also, they can regulate the
balance between the pro- and anti-inflammatory cytokines.6 Due to these beneficial effects,
probiotics have been suggested as a therapeutic option for IBS.6 Studies have found that
probiotics, specifically Bifidobacteria and certain probiotic combinations, improve symptoms of
IBS when taken in large amounts.2
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OBJECTIVE:
The objective of this selective EBM review is to determine whether or not the use of
probiotics treat abdominal pain in children between the ages of 4 and 18 with irritable bowel
syndrome.
METHODS
Three double-blind randomized controlled trials (RCTs) were used in this review. The
population studied included patients between the ages of 4 and 18 with irritable bowel syndrome.
The intervention used in all three RCTs was probiotics. The populations were compared to a
control group who were given a placebo. Outcomes measured in the study included abdominal
pain and abdominal discomfort.
“Irritable bowel syndrome” and “probiotics” were keywords used to narrow the search on
PubMed. All articles were published in English and in peer-reviewed journals. Articles were
selected by relevance to the clinical question and had patient oriented results (POEM). Studies
that were POEM’s, randomized controlled trials, and published after 2007 were included.
Cochrane systemic reviews, meta-analysis’s, and patients over the age of 18 were excluded.
Statistics used were relative risk reduction (RRR), absolute risk reduction (ARR), numbers
needed to treat (NNT), p-value, and mean change from baseline. Table 1 demonstrates the
demographics and characteristics of the reviewed studies.
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Table 1: Demographics and characteristics of included studies
Study
Type #pts Age Inclusion criteria Exclusion criteria W/D Interventions
(yrs.)
7
Basturk RCT
71 4-16 Patients who
Patients who are
5
Probiotic
(2016)
were diagnosed
not diagnosed with
treatment (5
with IBS
IBS.
x 109 CFU B.
according to the
Lactis) BID
Rome III criteria
PO x 4
in the Akdeniz
weeks.
University
Pediatric
Gastroenterology
outpatient clinic
between
September 2014May 2015.
1
Jadresin RCT
55 4-18 Patients who
Patients with
9
Probiotic:
(2016)
were diagnosed
underlying
citrus
with functional
diseases or has
flavored
abdominal pain
been treated with
450mg
and IBS at the
an
chewable
children’s
antibiotic/probiotic
tablet qd x
hospital Zagreg
7 days prior to
12 weeks.
from May 2012- enrollment.
The total
December 2014
value count
of L. reuteri
was 1 x
108live
bacteria
(CFU)/tablet
Kianifar6 RCT
60 4-18 Patients who
Patients with
8
Probiotic
(2015)
were diagnosed
underlying
capsule that
with IBS by a
diseases or taking
contained
pediatric
any medications
LGG at a
gastroenterologist
concentration
and have had
of 1x 1010
active symptoms
cfu/ml
of abdominal
bacteria and
pain for at least 2
inulin. BID x
weeks prior to
4 weeks.
the start of the
study.
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OUTCOMES MEASURED
The Basturk et al study, evaluated outcomes such as postprandial swelling, belchingabdominal distention, difficulty in defecation, urgent defecation, and feeling of incomplete
defecation. A self-reported questionnaire was used prior to treatment and post treatment. Patients
with improvement in all presenting symptoms were accepted as ‘fully benefited’ and those who
had resolution in one or several symptoms were accepted as ‘partially benefited’.1
The outcome from Kianifar et al, study evaluated severity of pain. A five-Likert scale
was used to specify the severity of the pain (0=very mild, 1= mild, 2= moderate, 3= severe, 4=
very severe).6 From both groups, outcomes were measured (placebo and probiotic) prior to
treatment and weekly for four weeks. Intervention lasted for four weeks.
Patients in the Jadresein et al study were given a diary to rate severity of pain on a daily
basis. The probiotic and placebo were discontinued after twelve weeks but rating severity of pain
daily continued for another four weeks. Even though patients were asked to record daily, they
were required to visit a certain hospital for evaluation on month one, three, and four. Symptoms
were evaluated using a faces scale (Wong-Baker FACES Pain Rating Scale; 0-no hurt-10 hurts
worst) for pain.1
RESULTS
Basturk et al study, included children between the ages of 4 and 16 years who were
diagnosed with IBS according to the Rome III criteria in the Akdeniz University Pediatric
Gastroenterology outpatient clinic between September 2014 and May 2015.7 The study did not
report an exclusion criteria for selecting patients. Family members of each patient disclosed a
written informed consent. Trial was double-blinded; forty-eight patients were randomized into an
experimental and control group. The experimental group which consisted of twenty-four patients
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received a probiotic (5x109 CFU B. lactis) twice a day for four weeks. The control group which
had twenty-four patients were given a placebo (900mg of inulin) twice a day for four weeks.
Self-reported questionnaires were used to evaluate the efficacy of probiotics in treating IBS.
Initially, there was no significant difference in symptoms between both groups.7 Chi-square test
was used to analyze the collected data from the self-reported questionnaire. In the probiotic
group, the most significant improvement observed was belching-abdominal fullness (p<0.001),
while there were also significant improvements in bloating after meals (p=0.016), and difficulty
with defecation (p=0.031).7 Full recovery was observed in seven patients (29.2%) in the
probiotic group and three patients in the placebo group (12.5%).7 When the groups were
compared with each other with regards to full recovery, there were no significant difference
between the prebiotics and probiotics, p= 0.155.7 Table 2 demonstrates the statistical
significance between both groups. Data demonstrated relative risk reduction of 45% and absolute
risk reduction of 21%. NNT is -4. NNT, numbers needed to treat, means for every 4 children
treated with probiotics it would prevent one fewer child from experiencing excruciating
abdominal pain, compared to the control group.
Table 2: Statistical significance at baseline and 4 weeks, belching-abdominal fullness
Before After
p-value
Probiotics 75%
25%
(n-24)
Placebo 54.2% 45.8%
(n=24)
Chi-square test was used.
*p-value £ 0.05 is significant

<0.001*
0.250
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Table 3: Efficacy of Basturk et al7 study.
% of participants,
% of participants,
within the comparison
within interventional
group, who experienced group, who experienced
belching-abdominal full belching-abdominal full
after 4 weeks (CER)
after 4 weeks (EER)
45.8%
25%

Relative
risk
reduction
(RRR)
45%

Absolute
risk
reduction
(ARR)

7

Numbers needed to
harm (NNT)

21%

-4 patients

In the Kianifar et al study, the inclusion criteria were patients age 4 to 18 years old who
had active symptoms of abdominal pain for at least two weeks before the beginning of the study
and had been diagnosed with IBS by a pediatric gastroenterologist.6 The diagnosis must have
been made on the basis of Rome III criteria and other differential diagnosis must have been
excluded by laboratory evaluation, abdominal ultrasound, radiographic imaging, endoscopy, and
breath hydrogen testing.6 Patients who are currently taking drugs or had an underlying disease
such as cardiac disease, renal disease, asthma, failure to thrive, cystic fibrosis were excluded.6
Sixty patients were initially selected however eight patients who were initially included were
excluded due to lack of follow up or due to a rise of another illness. Fifty-two participants were
randomly assigned to a control or interventional group. Twenty-six participants received a
probiotic (LGG 1x1010) twice per day for four weeks. Twenty-six participants received a placebo
(inulin) twice per day for four weeks. Patients were evaluated weekly with using the five-point
likert scale to specify severity of pain. Although no significant difference was obtained regarding
the baseline pain severity scales between the two groups, a statistically difference was observed
from one week after treatment.6 The p-value one week after treatment was <0.01. Data was
continuous and not convertible to a dichotomous format. Outcomes were measured before
intervention and weekly for four weeks in each group. Wilcoxan rank-sum test was used to
compare changes in abdominal pain (Table 4).
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Table 4: Pain severity before intervention and weekly for 4 weeks.
Pre-treatment 1week after
2 weeks after 3 weeks after
Treatment
treatment
treatment
Probiotic

2.5 ± 0.9

1.5±1.0

1.2±1.1

1.0±0.9

4 weeks
after
treatment
0.8±0.9

Inulin
(Placebo)
P-value

2.7±0.8

1.8±0.6

1.9±0.8

1.8±0.6

1.5±0.8

0.4

0.01

0.00

0.00

0.00
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In the Jadresin et al study, the inclusion criteria were children between age 4 and 18 years
old who had been diagnosed with IBS at the Children’s Hospital Zagreb from May 2012 to
December 2014.1 Patients who had a known or suspected immunodeficiency, treated with
probiotics and/or prebiotics seven days prior to enrollment, known neoplastic disorder, or any
other chronic disease were excluded.1 Written informed consent was obtained from the parent or
guardian of each child in the study as well as from children if older than nine years.1 Once
patients were randomized, they were asked to report back to the hospital monthly.1 Intervention
lasted twelve weeks and patients were followed four weeks after intervention.1 Children who
were non-compliant to treatment were excluded.1 Data was analyzed for fifty-five participants,
twenty-six received a probiotic (450mg L. reuteri 1x108) daily and twenty-nine received a
placebo daily. There was a difference between both groups in the number of days without pain,
with the median of 89.5 (range 5-108) days in the experimental group and 51 (range 0-107) days
in the placebo group (p=0.029).1 Participants taking the probiotic or inulin experienced
significant reduction in severity of abdominal pain from first to fourth month, although reduction
was more prominent in the experimental (probiotic) group (p<0.001 vs p=0.004) (table 5).1 No
adverse effects were reported. There was no significant differences in number of participants
with complete resolution of abdominal pain between probiotic and inulin group.1 Complete
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resolution of abdominal pain until the end of treatment (16 weeks) was seen in 16
(61.5%) participants from active group and 16 (55.2%) participants from placebo group
(p=0.633) (table 6).1 All patients, including the patients who discontinued the intervention, were
followed up until the end of the study; they were included into intention to treat analysis.1 Data
demonstrated relative benefit increase of 0.11% and absolute benefit increase 6.3%. NNT was
16. For every 16 children treated with probiotics it would prevent one fewer child from suffering
abdominal discomfort, comparted to the control group.
Table 5: Comparing severity of pain between beginning and end of treatment.
Severity of
Severity of
abdominal pain per
abdominal pain per
day in 1st month,
day in 4th month,
median (range)
median (range)
Probiotics (active)
0.75 (0-2.9)
0.21 (0-1.7)
Inulin (placebo)
0.96 (0.3-2.8)
0.6 (0-2)

P

<0.001
0.004

Assessed by Wong-Baker FACES Pain Rating Scale per group (Wilcoxon test)

Table 6: Efficacy of Jadresin et al study
Resolution of abdominal Resolution of abdominal
pain abdominal pain in
pain in the experiment
the control group
group (probiotics)
(placebo)
(EER)
(CER)
55.2%
61.5%

Relative
benefit
Increase
(RBI)
0.11%

Absolute
benefit
Increase
(ABI)

Numbers needed to
treat (NNT)

6.3%

16

Safe and Tolerability
In all three-randomized control trials no adverse events were reported in neither group.
Probiotics were well tolerated. Patients experiencing active IBS symptoms such as constipation,
diarrhea, or bloating probiotics did not aggregate or increase reoccurrence of IBS symptoms.
DISCUSSION
Irritable bowel syndrome is a condition that presents with various signs and symptoms.
The main cause of IBS is inconclusive; however, it is recognized to be multifactorial. The
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approach to managing irritable bowel syndrome is reducing the reoccurrence of gastrointestinal
pain and discomfort. Non-pharmaceutical and pharmaceutical therapies may be implemented
such as change in diet, exercising, counseling, medications.
Studies have been performed to determine the effectiveness of using probiotics to treat
IBS but in the adult population. It is challenging to conduct trials in the pediatric population
because there are more regulations such as receiving approval of the participants guardian. In the
pediatric population, few studies have been done and results are inconclusive. Kianifar et al
study, faced some limitations such as small sample size, short duration of treatment, and not
following up after cessation of treatment.6 Basturk et al study found probiotics effective in
children who have been diagnosed with IBS.7 However, a major limitation in the study was that
it was done in a tertiary health care center which meant dealing with relatively more complex
participants.7 Jadresin et al,study consisted of a small sample size. In future studies, long-term
treatment and long-term follow up can help evaluate the efficiency of probiotics. It is suggested
to conduct studies that include a large sample size, exclude patients who don’t have a history of
an underlying disease, and involve children from the general population to increase
generalizability.
CONCLUSION
Based on these three studies, probiotics can treat abdominal pain in children between the
ages of 4 & 18 with Irritable bowel syndrome. However, future research is warranted. Some ideas
to consider is involving children from general population to increase generalizability, have a larger
sample size, extend duration of study, and following up after cessation of treatment. Other items
to consider is determining if combination therapy is more effective than monotherapy.
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In the pediatric population, probiotics are being used to treat IBS. However, there has not
been significant research to prove that it has been effective.
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